|Articles|April 1, 2022
CGTLive’s Weekly Rewind – April 1, 2022
Author(s)GeneTherapyLive Staff
Review top news and interview highlights from the week ending April 1, 2022.
Advertisement
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. B-VEC Gene Therapy Heals Recessive Dystrophic Epidermolysis Bullosa Wounds
Beremagene geperpavec (B-VEC, Krystal Biotech) promotes durable wound healing in patients with recessive dystrophic epidermolysis bullosa (RDEB), according to preliminary data from the phase 3 GEM-3 trial (NCT04491604).
2. Renal Cell Carcinoma CAR T-Cell Therapy Fast Tracked
The FDA has granted fast track designation to Allogene Therapeutics’ chimeric antigen receptor (CAR) T-cell therapy ALLO-316 for the potential treatment of advanced or metastatic clear cell renal cell carcinoma (RCC).
3. Improving Speed and Fidelity of CRISPR/Cas9: Kenneth Johnson, PhD, and David Taylor, PhD
Kenneth Johnson, PhD, and David Taylor, PhD, professors and researchers from The University of Texas at Austin discussed new findings of Cas9 structure and mechanisms,
4. CAR T-Cell Expansion Indicative of Response in B-cell Lymphoma
Data from a prospective in vivo assessment suggest that good chimeric antigen receptor (CAR) T-cell expansion on day 10 (C10) after infusion could be an early biomarker to help predict response and survival in patients with B-cell lymphoma.
5. Liso-cel Shows Survival Benefit in R/R Large B-Cell Lymphoma
Lisocabtagene maraleucel (liso-cel, Breyanzi), a chimeric antigen receptor (CAR) T-cell therapy, demonstrated benefit to event-free survival (EFS) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025
- Trends in RNA Therapeutic Research
September 8th 2025
Advertisement
Advertisement
Trending on CGTlive®
1
Patients With DMD Treated With Avidity Biosciences’ Antibody Oligonucleotide Conjugate Del-Zota Show Functional Improvements
2
In Response to FDA’s Release of Full CRL for Deramiocel, Capricor Publishes Full Response to the Agency
3
Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
4